Platelet Aggregation Inhibitors

Thrombin is an enzyme in the blood that plays a key role in platelet formation during injury. While blood coagulation is essential for a surface wound, platelet activation underlies various pathological situations such as unstable angina pectoris, myocardial infarction and stroke. Thrombin is mediated by protease activated receptor-1 (PAR-1) which is expressed in the nervous system and in platelets. Once activated by thrombin, PAR-1 induces rapid and dramatic changes in cell morphology that is controlled by a series of localized ATP-dependent reactions. Technology: Researchers at the University of California have discovered specific creatine kinase inhibitors that inhibit thrombin-induced aggregation of platelets. These creatine kinase inhibitors could be used to treat a disease or disorder that is caused by pathological platelet aggregation.

US 6,444,695

Type of Offer: Licensing

Next Patent »
« More Biotech Patents
« More Pharmaceutical Patents

Share on      

CrowdSell Your Patent